Europe · Wires & real time · ANP

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

Published by ANP · Netherlands 9 h ago

SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtype ...

Read the full article on ANP Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (persportaal.anp.nl)

Also worth reading

TASS

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

Share

Also worth reading

European gas futures top $1,050, first time since December 2022

QatarEnergy signs deal to buy 4 million tons of US LNG annually through 2054

Hermes revenue growth slows as Chinese consumers cut spending on accessories

Millions of hacking attempts as companies, governments rush to patch PHP flaws

France's 24-year high borrowing costs could be 'warm up for Germany'

LSEG to buy Octus in $3.5 billion deal to shield from AI disruption